Reviewed by Dr Sarah Mitchell, PhD · Editorial Board
GLP-1 shortages and UK supply chain
A patient-facing reference for UK GLP-1 supply. Why shortages happen, where to check current status, what your prescriber and pharmacy can do, and why ‘order online instead’ is the answer most likely to put you on a counterfeit pen. Snapshot dated, refreshed when supply picture changes materially.
Why GLP-1 supply is tight
- Demand growth. Weight-management indications (Wegovy 2021, Mounjaro 2023 for T2DM and 2024 for weight) have added very large patient populations.
- Manufacturing scale-up. Peptide manufacturing at this scale is itself novel. Lilly and Novo have both invested heavily but new capacity takes years.
- Off-label use. Ozempic prescribed for weight management pulls supply away from diabetes patients.
- Global market. Supply is allocated globally and the UK competes for a share with the US, EU, and Asia.
How to find the current UK status
- Your dispensing pharmacy — the fastest source for what is and isn’t in stock locally.
- DHSC supply alerts — the UK Government issues alerts about medicine supply through DHSC and the Specialist Pharmacy Service.
- MHRA Drug Safety Updates — covers safety and recall information, often relevant during supply shifts where counterfeit risk is elevated.
What to do during a shortage
- Contact your prescriber. They have visibility of alternative products, current local supply, and the clinical context to advise you.
- Don’t skip doses without a plan. A short interruption (1–2 weeks) is usually OK; longer needs a re-titration plan when supply returns.
- Consider switching products. If Mounjaro is unavailable, Wegovy may be available; if Wegovy is unavailable, Mounjaro may be available; if neither, Saxenda is older but still licensed.
- Don’t bulk-buy. Beyond stockpiling being impractical (pen in-use limits, refrigeration), it competes with patients who need the medicine more urgently than you do.
What NOT to do
- Don’t buy online from non-UK pharmacies. Counterfeit GLP-1 supply surges during shortages. The Feb 2026 falsified Mounjaro 15 mg KwikPen alert came from supplies obtained outside the regulated UK chain.
- Don’t accept ‘compounded’ alternatives. Mass-market compounded GLP-1s marketed during shortages are the MHRA enforcement pattern, not a lawful workaround.
- Don’t buy from a friend or gym contact. Person-to-person supply of POMs is unlawful, and the source chain is unverifiable.
- Don’t double-up your dose to stretch supply. Adverse-event rates rise sharply with off-licence dosing.
Red-flag claims
If you see wording like this on a seller, clinic, or social-media advert, treat it as a warning sign rather than a benefit.
“Ozempic / Mounjaro available now while others are sold out”
‘Available now’ during a known shortage from an online seller is the exact pattern that produces counterfeit-pen incidents.
“Stock up before the next shortage”
Practical limits (in-use, refrigeration) make this impossible at scale and pulls supply from patients in greater need.
“Compounded semaglutide while Wegovy is short”
MHRA enforcement target. ‘Specials’ framework doesn't accommodate market-driven shortage as a clinical need.
“Use Ozempic instead — same active ingredient”
Worsens Ozempic supply for diabetes patients. The prescribing guidance is the opposite.
Sources & further reading
- Department of Health and Social Care — gov.uk
- MHRA Drug Safety Update — gov.uk
- Report a problem with a medicine or medical device — gov.uk
- MHRA — gov.uk